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S U M M A R Y
Background: HIV-1 infection has been shown to impact the outcome of patients with tuberculosis (TB),
but data regarding the impact of HIV-2 on TB outcomes are limited. The aim of this study was to assess
the impact of HIV types on mortality among TB patients in Guinea-Bissau and to examine the predictive
ability of the TBscoreII, a clinical score used to assess disease severity.
Methods: In a prospective follow-up study, we examined the prevalence of HIV-1, HIV-2, and HIV-1+2
co-infection in TB patients in Guinea-Bissau, and the impact on outcomes at 12 months of follow-up. We
included all adult TB patients in an observational TB cohort at the Bandim Health Project (BHP) in
Guinea-Bissau between 2003 and 2013 and assessed survival status at 12 months after the start of
treatment.
Results: A total 1312 patients were included; 499 (38%) were female (male/female ratio 1.6). Three
hundred and seventy-nine patients were HIV-infected: 241 had HIV-1, 93 had HIV-2, and 45 were HIV-
1+2 dual infected. The HIV type-associated risk of TB was 6-fold higher for HIV-1, 7-fold higher for HIV-
1+2 dual infection, and 2-fold higher for HIV-2 compared with the HIV-uninfected. Of the patients
included, 144 (11%) died, 62 (12%) among females and 82 (9%) among males (hazard ratio (HR) 0.91, 95%
conﬁdence interval (CI) 0.64–1.30; p = 0.596). Compared to male patients, female patients were younger
(1 year younger, 95% CI 0.5–2; p = 0.04), reported a longer duration of symptoms (14 days longer, 95% CI
4–25; p = 0.003), and had a higher TBscoreII (0.5 points more, 95% CI 0.3–0.7; p < 0.001). More females
than males were HIV-infected (36% vs. 25%; p < 0.001) and more females had a body mass index (BMI)
<15 kg/m2 (11% vs. 6%; p < 0.001) and a mid upper arm circumference (MUAC) <200 mm (13% vs. 7%; p
< 0.001). HIV infection increased the mortality risk, with HIV-1 infection displaying the highest HR (5.0,
95% CI 3.5–7.1), followed by HIV-1+2 (HR 4.2, 95% CI 2.2–7.8) and HIV-2 (HR 2.1, 95% CI 1.2–3.8). A
TBscoreII 4 was associated with increased mortality (HR 2.2, 95% CI 1.5–3.1). Signiﬁcantly increased
HRs were found for signs of wasting; a BMI <18 kg/m2 was associated with a HR of 1.8 (95% CI 1.3–2.6)
and a MUAC <220 mm with a HR of 3.8 (95% CI 2.7–5.2).
Conclusion: The HIV type-associated risk of TB was much higher for HIV-1 patients and higher but less so
for HIV-2 patients, compared with the HIV-uninfected. Clinical severity at presentation was also higher
for HIV-infected patients, although less so for HIV-2-infected patients, and all HIV-infected patients had
a poorer outcome than the uninfected; mortality was 4–5-fold higher for HIV-1 and dually infected
patients and two-fold higher for HIV-2-infected patients. These differences between HIV types did not
disappear after adjusting for CD4 count.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-
nc-sa/4.0/).
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The global burden of tuberculosis (TB) is falling, but is still
considerable. The World Health Organization (WHO) estimated
that there were 11 million prevalent cases of active TB and
1.5 million deaths from tuberculosis (TB) worldwide in 2013.1 The
targets for TB control are framed within the United Nations
Millennium Development Goals, the main goals being to reduce
TB incidence by 2015 and to halve the 1990 TB mortality by 2015,
which is now within reach on a global level.1 Many endemic
countries have no reliable health and death registration systems
and are therefore not able to assess progress in TB control or
trends in the TB burden. Such data are imperative for effective TB
control.2
A number of factors inﬂuence TB risk and outcome, but TB risk is
difﬁcult to assess without a known denominator, such as a well-
characterized population from which the TB cases are drawn, so
cases are not missed. Health and Demographic Surveillance Sites
(HDSS) are able to deliver such data, and over the last decades we
have followed the TB epidemic in Guinea-Bissau within such an
HDSS, The Bandim Health Project. During this period, HIV-2
prevalence has decreased markedly and HIV-1 has increased
dramatically.3 However, in the past decades a stable proportion of
approximately one third of TB patients have been co-infected with
one or more of the HIV types.4,5 HIV-1 is known to have a major
impact on both the risk of acquiring TB and the outcome of the
infection,6 but little is known regarding the impact of HIV-2 and
dual infection.
HIV-2 was discovered 2 years after HIV-1,7 and has mainly been
restricted to West Africa, where an estimated one to two million
people are infected with the virus.8 Compared with HIV-1, HIV-2 is
less transmissible (5- to 8-fold less efﬁcient than HIV-1 in early-
stage disease and rarely the cause of vertical transmission), and is
associated with a lower viral load and a slower rate of CD4+ cell
count decline.9 HIV-2 is associated with a slower clinical progres-
sion, but in a proportion of patients it will lead to AIDS with clinical
features indistinguishable from the syndrome caused by HIV-1. Yet,
the majority of HIV-2-infected individuals survive as long-term
non-progressors.8 Studies of HIV in Guinea-Bissau were initiated
early in the epidemic,7,10 and prevalence studies of HIV in Guinea-
Bissau in 1987 showed an HIV-2 prevalence of 9% in adults above the
age of 14 years in urban Bissau.11–13No HIV-1 infection was found at
that time. The ﬁrst case of HIV-1 infection was identiﬁed in 1989,
when one case of dual infection of HIV-1+HIV-2 was detected.11
Over the last 20 years the two viruses have shown different
patterns of spread in the country; the prevalence of HIV-2 seems to
be stabilizing or decreasing, while HIV-1 prevalence has been
increasing gradually. In contrast to the neighbouring countries of
Senegal and Guinea-Conakry, which both have a low HIV-1
prevalence (<1 and 1.5%, respectively), Guinea-Bissau has a
prevalence comparable to the levels of the most affected countries
in the sub-region, with an HIV-1 prevalence of 4% in the latest
survey.3 This survey found a decreasing HIV-2 prevalence of now
4.4%, but the prevalence was still high (>17% among women) in the
age group >45 years.
The lower prevalence of HIV-2 relative to HIV-1 and the
restricted dissemination of the HIV-2 epidemic have resulted in
limited numbers of studies on the impact of HIV-2 on other
infections such as TB. Our data from a high-burden TB area, which
is the epicentre of the HIV-2 epidemic, has allowed us to address
the impact of having one or more of the HIV types.
HIV co-infection is signiﬁcant for the disease severity of TB as
well as for the prognosis. There are limited data on the impact of
HIV-2 on TB from Guinea-Bissau, and these have shown a lower
mortality in HIV-2-infected patients,14 but not when adjusted for
CD4 count.15Most studies have looked at the extent of TB infection with a
laboratory perspective, using, for example, smear grade or biomark-
ers such as the sedimentation rate. Few studies have addressed the
impact of HIV on TB clinical severity because there has been a lack of
standardization of severity. Our group developed the Bandim
TBscoreII, which is a clinical tool for the assessment of disease
severity based on six signs and symptoms speciﬁc to TB disease.16–18
We have systematically collected information on symptoms and
have collected clinical signs for all TB patients enrolled in the TB
surveillance system in Bissau. The aim of the present study was to
relate this information to HIV data and long-term follow-up data also
collected in this cohort, with the overall objective of describing the
clinical presentation and severity for TB patients co-infected with
HIV-1, HIV-2, and HIV-1+2, as well as to describe differences in
mortality of TB patients according to the type of HIV co-infection.
2. Materials and methods
2.1. Study location
The study was conducted in the capital Bissau of the West
African country Guinea-Bissau, where the Bandim Health Project
has been an HDSS since 1978 (http://www.bandim.org). The
research has been based on the prospective collection of
demographic and health data by active household visits. Good
mapping, numbering of houses, and regular censuses have been
performed, making long-term follow-up possible in a country with
no civil registration. A central feature of the work in Guinea-Bissau
has been the attempt to follow long-term consequences of various
infections, health conditions, and interventions.
2.2. Epidemiology and study population
This study was based on a well-deﬁned area consisting of ﬁve
suburban areas in Bissau (Bandim 1, Bandim 2, Belem, Mindara,
and Cuntum). The area has a total population of 102 000 and all
individuals living in the area are registered by ID number, age, sex,
ethnic group, and socio-economic characteristics. Censuses are
performed at regular intervals and information on pregnancies,
births, mortality, and migration is collected on a daily basis. Since
1996, a surveillance system has detected all TB cases living in the
study area, and long-term follow-up has been possible in the
majority of cases. Guinea-Bissau has one of the highest TB
incidences in the world (279/100 000).5 We used the population
statistics indicated in this publication on incidence, as well as the
HIV prevalence ﬁgures from the latest survey in the study area.3
We estimated the population living with the various HIV types and
hypothesized that the inﬂux of new TB patients was minimal (or
that their HIV status was similar to the population living in the
study area). Hence, we estimated the 5-year TB risk from the
population living in the study area in 2006.
2.3. Study design
This was a longitudinal, prospective, cohort follow-up study.
2.3.1. Inclusion criteria
Patients were identiﬁed through daily visits by ﬁeld assistants
to the three health centres located in the study area and the
national referral TB hospital located next to the study area.
The diagnosis of TB was determined according to the WHO
criteria;19 both smear-positive cases diagnosed on the basis of
sputum microscopy for acid-fast bacilli (AFB) and smear-negative
cases diagnosed on the basis of clinical criteria after two courses of
antibiotics and X-ray were enrolled in the cohort. Extrapulmonary
cases were excluded from this study.
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the same day as the diagnosis was made, and invited for
consultation and enrolment. During treatment, patients were
followed through regular clinical evaluations; after the cessation of
treatment, mortality follow-up was conducted through house
visits.
2.3.2. Measurements
The severity of TB was assessed using the TBscoreII, recording
signs, symptoms, and anthropometry including the presence of
cough, chest pain, dyspnoea, and anaemia, body mass index (BMI),
and mid upper arm circumference (MUAC), with a maximal score
of 8. The TBscoreII has been validated in another cohort and has
been grouped into severity classes as follows: I (<2 points), II (2–3
points), and III (4 points).18Figure 1. Flow chart ofBlood samples were analyzed for HIV at the National Public
Health Laboratory in Guinea-Bissau using different tests over the
years. In 2003–2008, sera were screened using Enzygnost Anti-HIV
1/2 Plus (Behring Diagnostics GmbH, Marburg, Germany)
and reactive sera were conﬁrmed with Capillus HIV-1/HIV-2
(Cambridge Diagnostics, Galway, Ireland), as well as Immunocomb
II HIV-1&2 Bispot (Orgenics, Yavne, Israel). From 2008, a new
screening test was introduced, the Determine HIV-1/2 (Abbott
laboratories, Tokyo, Japan), and HIV type discrimination was
performed with SD Bioline HIV 1/2 3.0 (Standard Diagnostics,
Kyonggi-do, South Korea). This test has been shown to overesti-
mate the number of dually infected patients,20 and was replaced in
2012 with First Response HIV-1/HIV-2 WB (PMC Medical, Mumbai,
India) and from 2013 with Genie III HIV-1/HIV-2 (Bio-Rad,
Steenvorde, France). patients included.
Table 1
Baseline characteristics by HIV status, n (%)
HIV-1 HIV-2 HIV-1+2 Uninfected p-Value
Sex
Female 114 (47.3) 42 (45.2) 21 (46.7) 322 (34.5) 0.001
Male 127 (52.7) 51 (54.8) 24 (53.3) 611 (65.5)
Age, years
15–30 100 (41.5) 14 (15.1) 10 (22.2) 480 (51.5) <0.001
>30–40 80 (33.2) 29 (31.2) 15 (33.3) 193 (20.7)
>40–50 39 (16.2) 29 (31.2) 12 (26.7) 127 (13.6)
>50 22 (9.1) 21 (22.6) 8 (17.8) 133 (14.3)
Symptom duration
<2 weeks 12 (4.9) 3 (3.2) 3 (6.7) 34 (3.6) 0.018
2 weeks–2 months 59 (24.5) 22 (23.7) 9 (20.0) 290 (31.1)
>2–6 months 85 (35.3) 43 (46.2) 11 (24.4) 280 (30.0)
>6 months 85 (35.3) 25 (26.9) 22 (48.9) 329 (35.3)
Re-treatment
No 204 (86.4) 84 (90.3) 40 (88.9) 851 (92.7) 0.022
Yes 32 (28.3) 9 (7.9) 5 (4.4) 67 (9.3)
TBscoreII >4
No 115 (50.0) 50 (56.8) 22 (50.0) 536 (58.6) 0.097
Yes 115 (50.0) 38 (43.2) 22 (50.0) 379 (41.4)
BMI <17 kg/m2
No 205 (87.2) 84 (92.3) 39 (88.6) 867 (93.6) 0.009
Yes 30 (12.8) 7 (7.7) 5 (11.4) 59 (6.4)
MUAC <200 mm
No 197 (16.8) 81 (6.9) 38 (3.2) 858 (73.1) <0.001
Yes 37 (15.8) 10 (11.0) 7 (15.6) 65 (7.1)
CD4 (HIV-infected), cells/mm3
< 200 78 (33.5) 36 (33.5) 36 (40.5) NA 0.626
200–500 40 (17.1) 14 (15.7) 10 (23.3) NA
>500 115 (49.4) 39 (43.8) 20 (46.5) NA
BMI, body mass index; MUAC, mid upper arm circumference; NA, not applicable.
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ART was not widely available before 2007. Since then, all newly
diagnosed TB patients with a diagnosis of HIV have been referred to
a nearby ART facility for treatment. The vast majority of patients
diagnosed with TB in whom the HIV test was positive had no prior
knowledge of their HIV status and were therefore not on
treatment.
2.5. Statistics
Associations between TB and HIV were evaluated using odds
ratios (ORs) and their associated 95% conﬁdence intervals (CIs).
Univariate and multivariate analyses were performed using
logistic regression methods in Stata v.13 using Cox proportional
hazards, with time since the start of treatment as the underlying
time variable, adjusted for age and HIV. Univariate analyses were
performed separately for men and for women.
2.6. Ethical considerations
Permission for ongoing data collection was obtained from the
National Ethics and Health Committee at the Ministry of Health,
Bissau. Written information was given to all study participants in
the ofﬁcial language of Portuguese and oral information was given
to all eligible patients in the widely spoken language of Portuguese
Creole. Informed written consent, or a ﬁngerprint in the case of an
illiterate subject, has been kept together with the case report
forms.
3. Results
Recruitment began in November 2003 and ended in August
2013. Follow-up was completed in September 2014. We included
1312 patients with TB in our cohort; all patients had completed
their anti-TB treatment prior to September 1, 2013. An overview of
the patients enrolled in the data analysis is displayed in Figure 1. A
total of 379 patients were HIV-infected: 241 had HIV-1, 93 had
HIV-2, and 45 were HIV-1+2 dual infected. The mean age of the
patients was 35 years (range 15–90 years) and 499 (38%) were
females (male/female ratio 1.6).
Characteristics of the patients according to their HIV status are
displayed in Table 1. There were more males than females, but the
females were more often HIV-infected, in particular with HIV-1,
and were younger than males (1 year younger, 95% CI 0.5–2;
p = 0.04). HIV-1 was the most frequent co-infection, but in the
older age groups, HIV-2 was nearly as prevalent and dual infections
were more common.
3.1. Tuberculosis incidence
We used the HDSS registry to determine the total population
size and calculated the approximate number of HIV-infected usingTable 2




Male 24 422 879 (3.6) 
Female 28 432 1194 (4.2) 
Total 52 854 2073 
TB cases 2007–2011 638 118 
5-year risk/100 000 1207 5692 
RR of TB (95% CI) - 6.6 (5.9–6.2) 
TB, tuberculosis; RR, relative risk; CI, conﬁdence interval.prevalences from an earlier survey in order to estimate the total
number of HIV-1, HIV-2, and dually infected subjects in the
population. We used the population in 2006 as reported in Lemvik
et al.5 and the HIV prevalences reported in the article by da Silva
et al.3 to estimate the total number of HIV-infected in 2006
(Table 2). In our current TB cohort, we then used the total number
of TB patients included in the years 2007–2011 to calculate the 5-
year TB risk (Table 2). These estimates led to 6–7-fold higher TB
risk ratios (RR) among HIV-1 and dually infected subjects and a 2-
fold higher risk for HIV-2 patients (Table 2). Dually infected
patients had a 5-year TB RR of 1.3 (95% CI 1.2–1.3) compared with
HIV-1 single infected, and the RR for dual-infected vs. HIV-2
patients was 3.4 (95% CI 3.3–3.5). For HIV-1 vs. HIV-2 the RR was
2.7 (95% CI 2.6–2.7).
3.2. Clinical presentation
One hundred and thirteen (9%) were retreatment cases; this
was more frequent among HIV-1-infected subjects (28% were
retreated). Two thirds of the patients, 880/1312 (67%), had a long
duration of symptoms (>2 months) prior to TB diagnosis and this









659 (2.7) 83 (0.34) 22 801 (93.4)
1108 (3.9) 165 (0.58) 25 965 (91.3)
1767 248 48 766
38 18 464
2150 7258 951
2.3 (2.2–2.4) 7.7 (7.5–7.8) 1
Figure 2. Survival according to HIV status.
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the mean TBscoreII was 3.6 (95% CI 5.5–3.7) and 43% (554/1277) of
the patients had a TBscoreII 4, which is deﬁned as high severity.18
Among HIV-1-infected patients, 50% (115/230) had a TBscoreII 4;
for HIV-2 this was 43% (38/88) and for those with a dual infection it
was 50% (22/44). Nutritional status constitutes a major part of the
TBscoreII, and both BMI and MUAC were markedly low in a high
proportion of patients and signiﬁcantly associated with the HIV
type; patients with HIV-1 and the dually infected had particularly
low BMI and MUAC (Table 1).
Compared with the men, the women had a longer duration of
symptoms (14 days longer, 95% CI 4–25; p = 0.003), a signiﬁcantly
higher TBscoreII (0.5 points more, 95% CI 0.3–0.7; p < 0.001), and
more had a BMI <18 kg/m2 (48% vs. 38%; p = 0.003) and a MUAC
<220 mm (31% vs. 19%; p < 0.001) (Table 3).
3.3. Outcome
The standard TB outcomes are displayed in Figure 1; the
proportion of successful treatment (cure or completed) was close
to the WHO goal of 85% (80%). During the treatment period, a total
of 106/1312 (8%) patients died, and during the entire 12-month
follow-up period, 144/1312 (11%) died (Table 4). Patients above
the age of 30 years had a higher risk of dying, in particular those
aged >50 years (HR 2.8, 95% CI 1.7–4.4). All HIV single and dual
infected patients had signiﬁcantly increased mortality (Table 4),
with an adjusted HR above 2 for HIV-2 and nearly 5 for HIV-1 and
dual infection. Mortality according to the HIV type is displayed in
Figure 2. When adjusting for CD4 count at TB diagnosis, we found
that this changed the mortality by HIV type only a little, and the
adjusted HR for death for HIV-2 vs. HIV-1 was 0.49 (95% CI 0.27–
0.89).
As expected, we found a marked excess mortality for patients
presenting with a high TBscoreII (Figure 3). The mortality rate ratio
for patients with a high severity at inclusion was twice as high as
for patients with a low severity. This was also seen after adjusting
for CD4 count, which was only decreased for the HIV co-infected
patients.
Treatment outcome did not differ signiﬁcantly by gender
(Figure 1). However, the tendency was that more females than
males completed treatment/died and more males than females
abandoned treatment.Table 3










15–30 253 (50.7) 351 (43.2) 604 (46.0) 0.041
>30–40 105 (21.0) 212 (26.1) 317 (24.1)
>40–50 71 (14.2) 136 (16.7) 207 (15.8)
>50 70 (14.0) 114 (14.0) 184 (14.0)
HIV
Uninfected 322 (64.5) 611 (75.2) 933 (71.1) 0.001
HIV-1 114 (22.9) 127 (15.6) 241 (18.4)
HIV-2 42 (8.4) 51 (6.3) 93 (7.1)
HIV-1+2 21 (4.2) 24 (2.9) 45 (3.4)
Symptom duration
<2 weeks 19 (3.8) 33 (4.1) 52 (3.9) 0.005
2 weeks–2 months 117 (23.5) 263 (32.4) 380 (28.9)
>2–4 months 177 (35.5) 242 (29.8) 419 (31.9)
>4 months 186 (37.3) 275 (33.8) 461 (35.1)
Re-treatment 41 (8.2) 72 (8.9) 113 (8.6) 0.756
TBscoreII 4 242 (48.5) 312 (38.4) 575 (42.2) <0.001
BMI <18 kg/m2 241 (48.3) 334 (41.1) 575 (43.8) 0.003
MUAC <220 mm 150 (30.6) 156 (19.2) 306 (23.3) <0.001
BMI, body mass index; MUAC, mid upper arm circumference.4. Discussion
With the use of HDSS data on the population and existing HIV
prevalence survey data, we were able to demonstrate the different
TB risks according to the type of HIV infection. The outcome
differed substantially by HIV status, even when adjusting for CD4.
We found that the outcome of having TB is poorer when the subject
is HIV-infected, mostly for HIV-1 and those with HIV-1+2 dual
infections, but also for HIV-2. The TBscoreII prediction of mortality
was not inﬂuenced by HIV status.
The higher TB risk for those with a dual infection could be
interpreted as a sign of dual infection being worse than HIV-1
single infection. However, this may not necessarily be the case.
Esbjo¨rnsson et al. have shown protective effects of having HIV-2
prior to HIV-1,21 and while several other reports have shown that
the dually infected have similar mortality to those with an HIV-1
single infection,22 it is most likely because of the time point at
which the dually infected are diagnosed,9 which is often at a time
of advanced HIV disease, such as in these patients with active TB.
With the data available we cannot clarify whether the dually
infected patients were ﬁrst infected with HIV-2 and whether this
delayed their progression to AIDS.
Previous studies have shown increased mortality for HIV co-
infected TB patients,14,23–25 increased age,23–30 and wasting,14,25,31
which is in line with our ﬁndings. However, data on the relationship
between clinical severity and mortality are sparse and the
availability of clinical severity data in this study is a strength.
Gender differences in TB severity and treatment outcome are
seldom assessed. While women are less likely to be diagnosed with
TB32–36 and referred to treatment, they are shown to follow
through at higher rates than males,33–37 and are more often HIV co-
infected.34 The latter two observations are also reﬂected in our
data. The increased severity shown here could reﬂect the delay in
health-seeking/referral to treatment and the increased HIV co-
infection amongst females. Further, it has been suggested that
females progress to disease at earlier ages,38 which could be the
reason for the age difference in our cohort.
A strength of this study is that it is by far the largest cohort of TB
patients with HIV-2 and dual co-infection reported. Our ﬁndings
are in contrast to those of van der Sande et al. from a large Gambian
HIV cohort with several HIV-2 and dually infected patients, of
whom 368 were diagnosed with TB.15 They also found large
survival differences between the HIV-1 and HIV-2 infected, but the
difference disappeared when adjusting for CD4 count, suggesting
that it is the degree of advanced HIV disease that is important,
rather than the HIV type. HIV-2 has a slower and more infrequent
progression towards immunodeﬁciency, and the ﬁndings of
van der Sande et al. suggest that HIV-2 patients with advanced
Table 4
















Female 499 62 (12.4) 453.3 62/453.3 1 1
Male 813 82 (10.1) 735.8 82/735.8 0.81 (0.59–1.13) 0.94 (0.67–1.31)
Age, years
15–30 604 37 (6.1) 562.7 37/562.7 1 1
>30–40 317 47 (14.8) 278.0 47/278.0 2.55 (1.66–3.93) 1.88 (1.21–2.91)
>40–50 207 26 (12.6) 185.2 26/185.2 2.12 (1.28–3.50) 1.60 (0.96–2.66)
>50 184 34 (18.5) 163.2 34/163.2 3.15 (1.98–5.01) 2.76 (1.73–4.40)
HIV
Uninfected 933 56 (6.0) 875.0 56/875.0 1 1
HIV-1 241 62 (25.7) 193.8 62/193.8 4.89 (3.41–7.02) 4.97 (3.46–7.14)
HIV-2 93 14 (15.1) 82.9 14/82.9 2.62 (1.46–4.71) 2.10 (1.16–3.80)
HIV-1+2 45 12 (26.7) 37.4 12/37.4 4.94 (2.65–9.21) 4.19 (2.24–7.84)
CD4 countc, cells/mm3
>500 127 20 (15.8) 108.5 20/108.5 1 1
200–500 64 7 (10.9) 59.8 7/59.8 0.64 (0.27–1.51) 0.64 (0.27–1.52)
<200 174 61 (35.1) 133.3 61/133.3 2.43 (1.47–4.03) 2.47 (1.49–4.09)
Symptom duration
<2 weeks 52 3 (5.8) 49.4 3/49.4 1 1
2 weeks–2 months 380 34 (8.9) 348.7 34/348.7 1.61 (0.49–5.23) 2.05 (0.63–6.67)
>2–4 months 419 42 (10.0) 381.8 42/381.8 1.80 (0.56–5.81) 1.97 (0.61–6.37)
>4 months 461 65 (14.1) 409.2 65/409.2 2.60 (0.82–8.28) 2.92 (0.92–9.31)
Re-treatment
No 1179 124 (10.5) 1071.2 124/1071.2 1 1
Yes 113 20 (17.7) 98.9 20/98.9 1.74 (1.09–2.79) 1.24 (0.77–2.00)
TBscoreII 4
No 723 51 (7.1) 676.7 51/676.7 1 1
Yes 554 84 (15.2) 484.1 84/484.1 2.29 (1.62–3.24) 2.16 (1.53–3.06)
BMI <18 kg/m2
No 721 56 (7.8) 667.8 56/667.8 1 1
Yes 575 81 (14.1) 510.8 81/510.8 1.88 (1.34–2.65) 1.83 (1.30–2.58)
MUAC<220 mm
No 986 68 (6.9) 919.4 968/919.4 1 1
Yes 306 75 (24.5) 251.1 75/251.1 3.99 (2.88–5.45) 3.76 (2.69–5.23)
HR, hazard ratio; CI, conﬁdence interval; BMI, body mass index; MUAC, mid upper arm circumference.
a Time since start of treatment as the underlying time variable.
b Time since start of treatment as the underlying time variable, adjusted for age and HIV.
c Only HIV-infected, n = 379.
C. Wejse et al. / International Journal of Infectious Diseases 32 (2015) 128–134 133disease are at the same risk as HIV-1 and dually infected patients at
the same stage. Our study population is markedly different, being a
TB cohort in which some have HIV; the Gambian cohort comprised
HIV patients some of whom were diagnosed with TB. Hence, in our
population there were more patients with advanced disease in
which TB was a part of AIDS, also among the HIV-2 infected, with a
similar proportion as among the HIV-1-infected (one third of the
patients) having a CD4 count below 200 cells/mm3. Adjusting for
low CD4 did not, therefore, change estimates much, and our resultsFigure 3. Mortality according to clinical severity at TB treatment start, with 95%
conﬁdence intervals.indicate that even at the same low CD4 levels, HIV-2 is still
associated with a survival beneﬁt with simultaneous TB compared
with HIV-1–TB-co-infection.
A weakness of this study is that we did not have individual-
ized data on HIV status in the background population, but used
survey data to estimate the number infected. Our TB incidence by
HIV type is therefore based on the observation of TB cases over a
5-year period and knowledge of the size of the population, as
well as the distribution of HIV types, and not on real-time
observation of TB risk in a cohort of HIV-infected subjects. This is
an approximation, and so is the presumption that most of the TB
patients enrolled in our cohort were long-term residents in the
study area. There may have been some inﬂux of HIV-infected
patients from villages into the capital Bissau to seek treatment,
and this could have biased our estimation towards a higher risk
of TB among HIV-infected subjects than was actually the case.
However, we know that only a minority of the TB patients had
recently migrated into the study area, so we consider this is
minor source of bias.
Another limitation of this study was the lack of conﬁrmatory
HIV type discriminatory testing for the entire study period. In the
last part of the study, the conﬁrmation of HIV type was done using
a second Bioline, which has been shown to be inaccurate, in
particular with regard to HIV-1+2 dual infection.20 There may
therefore be patients identiﬁed as HIV-1 single infection in our
data, who are in fact dually infected. This potential bias likely did
not have a major impact on our ﬁndings since the differences
between HIV-1 and dually infected subjects were small.
C. Wejse et al. / International Journal of Infectious Diseases 32 (2015) 128–134134Our ﬁndings underline the importance of immediate referral to
ART facilities for treatment for TB patients newly diagnosed with
HIV, regardless of the type. HIV co-infected patients presented
with a more severe clinical status and displayed excess mortality
even in the ﬁrst month of TB treatment. Hence, rapid HIV diagnosis
for all new TB patients is of the utmost importance. We also found
that the TBscoreII was an easily obtainable measure to identify
which patients were at risk, unaffected by HIV status, and this
could be used in the triage of patients.
In conclusion we have documented that the HIV type-
associated risk of TB is 6-fold higher for HIV-1-infected patients,
7-fold higher for the HIV-1+2 dually infected, and 2-fold higher for
HIV-2 single infected, compared with the HIV-uninfected. Clinical
severity at presentation was also higher for the HIV-infected,
mostly for HIV-1 and dually infected patients and least for the HIV-
2 infected. All HIV-infected subjects had poorer outcomes than the
uninfected, with a 4–5-fold higher mortality for HIV-1 and dually
infected patients and 2-fold higher for the HIV-2 infected, although
the differences between HIV types disappeared after adjusting for
CD4 count.
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